Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012:2012:158075.
doi: 10.1100/2012/158075. Epub 2012 Dec 11.

Predictors of acquired perforating dermatosis in uremic patients on hemodialysis: a case-control study

Affiliations
Randomized Controlled Trial

Predictors of acquired perforating dermatosis in uremic patients on hemodialysis: a case-control study

Cheng-Hao Weng et al. ScientificWorldJournal. 2012.

Abstract

Objectives: The purpose of this study was to identify the predictors of acquired perforating dermatosis (APD) in patients on maintenance hemodialysis (HD).

Methods: A case-control study was performed at our outpatient HD center between January 1, 2000 and March 31, 2011. Patients on HD with APD were matched (1 : 2) for gender and age with controls on HD. Conditional logistic regression was used to identify factors associated with APD.

Results: A total of 19 patients with APD and 38 age and gender matched patients were enrolled in the study. Univariate logistic regression showed that APD was significantly associated with diabetes mellitus (DM), reduced levels of intact parathyroid hormone (iPTH) and albumin (Alb), reduced dialysis adequacy (Kt/V) and urea reduction rate (URR), and elevated levels of high-sensitivity C-reactive protein (hsCRP). Multivariate logistic regression identified reduced iPTH (hazard ratio (HR): 0.983; P = 0.026) and Alb (HR: 0.099; P = 0.047) and elevated hsCRP (HR: 1.210, P = 0.024) as risk factors for APD.

Conclusions: iPTH, hsCRP, and Alb are predictors for APD in HD patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ROC curve for iPTH (AUROC = 0.776 ± 0.067; 95% CI: 0.645–0.906; P = 0.001).

Similar articles

Cited by

  • Cutaneous manifestations of ESRD.
    Galperin TA, Cronin AJ, Leslie KS. Galperin TA, et al. Clin J Am Soc Nephrol. 2014 Jan;9(1):201-18. doi: 10.2215/CJN.05900513. Epub 2013 Oct 10. Clin J Am Soc Nephrol. 2014. PMID: 24115194 Free PMC article. Review.

References

    1. Kreuter A, Gambichler T. Acquired reactive perforating collagenosis. Canadian Medical Association Journal. 2010;182(4):p. E184. - PMC - PubMed
    1. Lynde CB, Pratt MD. Acquired perforating dermatosis: association with diabetes and renal failure. Canadian Medical Association Journal. 2009;181(9):p. 615. - PMC - PubMed
    1. Maurice PDL. Acquired perforating dermatosis in renal patients. Nephrology Dialysis Transplantation. 1997;12(12):2774–2775. - PubMed
    1. Andress DL, Endres DB, Maloney NA. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. Journal of Clinical Endocrinology and Metabolism. 1986;63(5):1163–1169. - PubMed
    1. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American Journal of Kidney Diseases. 2003;42:S1–S201. - PubMed

Publication types